Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12675MR)

This product GTTS-WQ12675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12675MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1024MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9563MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ226MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ10857MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ12051MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ12542MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ15298MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ8402MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW